These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18449408)

  • 1. Therapeutic integrin inhibition: allosteric and activation-specific inhibition strategies may surpass the initial ligand-mimetic strategies.
    Ahrens I; Peter K
    Thromb Haemost; 2008 May; 99(5):803-4. PubMed ID: 18449408
    [No Abstract]   [Full Text] [Related]  

  • 2. A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists.
    Bassler N; Loeffler C; Mangin P; Yuan Y; Schwarz M; Hagemeyer CE; Eisenhardt SU; Ahrens I; Bode C; Jackson SP; Peter K
    Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):e9-15. PubMed ID: 17170374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.
    Armstrong PC; Peter K
    Thromb Haemost; 2012 May; 107(5):808-14. PubMed ID: 22370973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mechanism of alphaIIbbeta3 antagonism by savignygrin and its implications for the evolution of anti-hemostatic strategies in soft ticks.
    Mans BJ; Neitz AW
    Insect Biochem Mol Biol; 2004 Jun; 34(6):573-84. PubMed ID: 15147758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activating effects of GPIIb/IIIa blockers: an intrinsic consequence of ligand-mimetic properties.
    Peter K; Schwarz M; Bode C
    Circulation; 2002 May; 105(21):E180-1. PubMed ID: 12034670
    [No Abstract]   [Full Text] [Related]  

  • 6. Membrane proteins up for grabs.
    von Heijne G
    Nat Biotechnol; 2007 Jun; 25(6):646-7. PubMed ID: 17557100
    [No Abstract]   [Full Text] [Related]  

  • 7. Ligand-binding assays: fibrinogen.
    Cox D
    Methods Mol Biol; 2004; 273():125-38. PubMed ID: 15308798
    [No Abstract]   [Full Text] [Related]  

  • 8. The disintegrin echistatin stabilizes integrin alphaIIbbeta3's open conformation and promotes its oligomerization.
    Hantgan RR; Stahle MC; Connor JH; Lyles DS; Horita DA; Rocco M; Nagaswami C; Weisel JW; McLane MA
    J Mol Biol; 2004 Oct; 342(5):1625-36. PubMed ID: 15364586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrete functional motifs reside within the cytoplasmic tail of alphaV integrin subunit.
    Haas TA
    Thromb Haemost; 2008 Jan; 99(1):96-107. PubMed ID: 18217140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invited commentary.
    Hiramatsu Y
    Ann Thorac Surg; 2005 Jul; 80(1):257-8. PubMed ID: 15975377
    [No Abstract]   [Full Text] [Related]  

  • 11. Conformation-Specific Blockade of αIIbβ3 by a Non-RGD Peptide to Inhibit Platelet Activation without Causing Significant Bleeding and Thrombocytopenia.
    Shen C; Liu M; Tian H; Li J; Xu R; Mwangi J; Lu Q; Hao X; Lai R
    Thromb Haemost; 2020 Oct; 120(10):1432-1441. PubMed ID: 32717755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-platelet approach targeting the fibrinogen ligand of the GPIIB/IIIa receptor.
    Tsikaris V
    J Pept Sci; 2004 Oct; 10(10):589-602. PubMed ID: 15526708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61).
    Schwarz M; Katagiri Y; Kotani M; Bassler N; Loeffler C; Bode C; Peter K
    J Pharmacol Exp Ther; 2004 Mar; 308(3):1002-11. PubMed ID: 14617694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redox modulation of integrin [correction of integin] alpha IIb beta 3 involves a novel allosteric regulation of its thiol isomerase activity.
    Walsh GM; Sheehan D; Kinsella A; Moran N; O'Neill S
    Biochemistry; 2004 Jan; 43(2):473-80. PubMed ID: 14717602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of novel platelet fibrinogen receptor antagonists with 2H-1,4-benzoxazine-3(4H)-one scaffold. A systematic study.
    Anderluh M; Cesar J; Stefanic P; Kikelj D; Janes D; Murn J; Nadrah K; Tominc M; Addicks E; Giannis A; Stegnar M; Dolenc MS
    Eur J Med Chem; 2005 Jan; 40(1):25-49. PubMed ID: 15642407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation.
    Straub A; Wendel HP; Dietz K; Schiebold D; Peter K; Schoenwaelder SM; Ziemer G
    Thromb Haemost; 2008 Mar; 99(3):609-15. PubMed ID: 18327411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple N-methylation by a designed approach enhances receptor selectivity.
    Chatterjee J; Ovadia O; Zahn G; Marinelli L; Hoffman A; Gilon C; Kessler H
    J Med Chem; 2007 Nov; 50(24):5878-81. PubMed ID: 17973471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allicin and disulfiram enhance platelet integrin alphaIIbbeta3-fibrinogen binding.
    Manaster Y; Shenkman B; Rosenberg N; Savion N
    Thromb Res; 2009 Sep; 124(4):477-82. PubMed ID: 19632706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation?
    Aukrust P; Damas JK; Solum NO
    J Am Coll Cardiol; 2004 Jun; 43(12):2326-8. PubMed ID: 15193701
    [No Abstract]   [Full Text] [Related]  

  • 20. αIIbβ3: structure and function.
    Coller BS
    J Thromb Haemost; 2015 Jun; 13 Suppl 1(Suppl 1):S17-25. PubMed ID: 26149019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.